Introduction
Cationic liposome-DNA complexes (lipoplexes) 1 are used as the most favorable non-viral nucleic acid delivery system in vitro and in vivo. Several lipoplexes based on various formulations of cationic lipids are serving in clinical trials in cases of cystic fibrosis 2 or cancer. 3 In vitro transfection using lipoplex-mediated gene delivery in cultured cells showed relatively high expression of a reporter gene. [4] [5] [6] However, these lipoplexes show very poor expression in vivo. For in vivo transfection, lipoplexes are required to reach the target cells; therefore the first obstacle is their interaction with the biological milieu at the site of injection (ie blood, in the case of intravenous administration). Successful transfection in vitro was carried out under conditions of net positive charge of lipoplexes due to excess of cationic lipid positive charges over DNA negative charges. 7, 8 Recent experiments suggest that in vivo, and especially for i.v. delivery, this excess of positive charge has to be larger than in vitro. 9 Since the development of early transfection kits, 10 it became clear that for many of them the biological milieu, such as serum, inhibits transfection efficiency, and the higher the serum (or plasma) percent the larger is the inhibition. [11] [12] [13] Preliminary results 7 indicate that these results are related to physical changes occurring in lipoplexes in the biological milieu. Various approaches were recently introduced in order to overcome this discrepancy between successful in vitro transfection and the much less successful in vivo transfection. Since lipoplexes have not been as efficient as viral vectors for in vivo gene delivery, much effort has been devoted to synthesis of new cationic lipids that are more serum resistant; 12, 14, 15 changing helper lipids; 16, 17 stabilization of the complexes by DNA-condensing agents such as polyamines and protamine sulfate; and steric stabilization of lipoplexes by poly (ethylene glycol) (PEG) phospholipid conjugates. 16, [18] [19] [20] These studies make it clear that for improved in vivo gene delivery it is necessary to understand the interaction of lipoplexes with blood components. Indeed, the interaction of complexes with plasma proteins has been studied to some degree, 21, 22 but almost no information is available on the interaction of lipoplexes with RBC and about the interplay of lipoplex/plasma components (proteins and low molecular weight components)/blood cells. Much is known about how size, lamellarity, and lipid composition affect plasma pharmacokinetics and biodistribution of liposomes. 21, 23, 24 Cationic liposomes containing stearylamine 25 or aminoglycolipids 26 were shown to be accumulated in the liver and spleen after i.v. injection. However, studies show that most of the gene expression following systemic injection of lipoplexes based on cationic lipids, such as DOTMA {N-[2,3-(dioleyloxy)propyl]-N,N,N-trimethylammonium bromide} 27, 28 or DDAB (dimethyldioctadecylammonium bromide), 16 occurred in the lung. It was suggested that the reasons for lipoplex localization in the lung is related to the increase in size of lipoplex in the plasma. 24 However, another mechanism for such localization, agglutination of RBC by the lipoplex to form lipoplex-RBC agglutinates, should also be considered.
This study is aimed at gaining some insight on lipoplex/plasma/RBC interactions in order to better understand lipoplex biodistribution after i.v. administration, with the aim of defining conditions under which intravenous injection of complexes will be more effective. Understanding of this interplay may be important, not only for trying to improve transgene activity in vivo, but also to explain organ/tissue localization of the expressed genes.
Results

Basic characterization of media
To study the effect and the role of serum or plasma, high molecular weight components >14 kDa (HMWC), and low molecular weight components Յ14 kDa (LMWC) in the interaction between lipoplexes and RBC, five different media were characterized (Table 1) : (1) native serum, which contains both HMWC (mainly proteins) and LMWC (ions and other components) without anticoagulant; (2) plasma, which, in addition to proteins and LMWC, contains sodium citrate as anticoagulant; (3) HMWC, obtained after dialysis of the plasma through a 14-kDa membrane; (4) LMWC, which contains mostly ions and low MW organic compounds, and citrate as anticoagulant; (5) 0.15 M NaCl. The characterization included concentration of total proteins, concentration of primary amino groups (to give information about positively charged groups derived from organic molecules in the media, which can compete with cationic lipids in the association with DNA), osmotic pressure (a function of particle concentration), and conductivity (to assess ionic strength). Most of the proteins are in the HMWC. Conductivity and osmolality measurements indicate that Gene Therapy most of the ionic strength is derived from LMWC. In addition, we looked at direct interaction between RBC and lipoplexes in electrolyte-and protein-free medium (5% dextrose). The data showed a large effect of the medium composition on RBC hemagglutination induced by lipoplexes, the serum being the most potent medium in inhibiting hemagglutination. The media in which the complexes were incubated decreased the hemagglutination of RBC by lipoplexes in the following order: serum > HMWC > 0.15 M NaCl > 5% dextrose.
Effect of lipoplex charge on interaction with RBC
In vivo i.v. injection of complexes containing cationic carriers and DNA for gene delivery purposes is usually done with an excess of positive charge. 16, 17, 20 During all the in vitro experiments we tried to imitate such in vivo conditions of i.v. injection, in which complexes containing 50 g DNA and various amounts of cationic carriers are injected, in a total volume of 250 l, into a mouse (having~1 ml of blood, 500 l serum). We maintained this ratio of complex to all blood components: 5 l of complexes (1 g DNA) was incubated with 10 l of serum, HMWC, 0.15 M NaCl, or 5% dextrose. To enable follow-up of the agglutination, 1% RBC has to be used. 29 Therefore in order to keep the ratio of lipoplex:RBC similar to in vivo conditions, the lipoplex-medium suspension was diluted 1:100, and was incubated 1. and 2.0, Ϫ/+) were allowed to interact with several dilutions of plasma (5, 25, and 90%). The lipoplexes used in this study are complexes formed as a result of interaction of DNA with cationic liposomes containing F-PE, a pH-and surface potential-sensitive fluorophore. 30 This allows changes in liposome electrostatics to be followed and the formation of lipoplex, which is driven by the mutual neutralization of the cationic lipid and the polyanionic DNA. 31, 32 In order to follow the effects of plasma on lipoplex electrostatics, the fluorophore used as a lipoplex sensor must be non-exchangeable and non-transferable with/to an amphipathic or hydrophobic environment (such as plasma lipoproteins). The 4-heptadecyl-7-hydroxycoumarin used by Zuidam and Barenholz 31, 32 does not meet this condition, and therefore in this study we used phosphatidylethanolamine (PE) to which a fluorescein moiety was covalently attached to the PE headgroup (F-PE), as this molecule stays in the assembly even in 100% plasma and can be used to study liposome pharmacokinetics. 33 The higher the local pH and the more positive the local electrical potential, the higher is the fluorescence intensity. 30, 34 The decrease in the ratio of fluorescence intensity of lipoplex in plasma to its fluorescence intensity in Hepes buffer, referred to as F(lipp/p)/F(lipp/b), indicates the extent of interaction between plasma and lipoplex; the lower the ratio, the higher the interaction (Figure 3 ). This ratio drastically decreased with increase in plasma concentration. Increasing the amount of DNA in the complex (Ϫ/+ ratio of 2.0) resulted in a smaller effect, which suggests that DNA reduces the interaction between the lipoplex and the plasma components.
Effect of blood source and blood type
We tested whether lipoplex-induced hemagglutination is a general phenomenon or is dependent on the source (mouse or human) and/or on the blood type. Therefore we incubated lipoplexes of DOTAP/CHOL in various Ϫ human blood types. In both cases similar hemagglutination (with minor differences) occurred, as described in Figure 1 . Agglutination also occurred using mouse blood, indicating that the hemagglutination induced by lipoplexes is a general phenomenon and occurs irrespective of blood source and/or human blood type.
Effect of lipoplex to RBC ratio
One important difference between the in vivo i.v. injection of lipoplexes and the in vitro experiments presented in this paper is that for in vivo injections into the bloodstream the ratio of lipoplex to RBC at the site of injection is larger (though unknown) than in vitro, after mixing the lipoplexes with RBC to reach an equivalent ratio to this in the total mouse blood. Therefore total lipoplex to RBC ratio at the site of injection is higher than in the in vitro mixing experiment, where mixing is immediate. In order to assess this hypothesis we repeated the experiment described above by varying the concentration of RBC in the range 0.5-2.0%. The experiment was performed in serum. The ratio of the lipoplexes to RBC is definitely an important contributor to the level of hemagglutination, and the higher this ratio the larger is the level of agglutination ( Figure 4 ). However, no agglutination occurred at ratio L + /DNA Ϫ below 3.0 at all lipoplex to RBC ratios used. It is possible, however, that in vivo the ratio of lipoplexes to RBC is even higher, and therefore hemagglutination may occur at a somewhat lower L + /DNA Ϫ ratio than 3.0. Also it is possible that there is a threshold ratio under which the serum will neutralize the lipoplex charges completely, and therefore no hemagglutination and no transfection will occur. Experiments are now under way to test this hypothesis.
Interaction between RBC and different formulations containing DOTAP/CHOL
Recently it was demonstrated that modifications of lipoplexes by using either DNA condensing agents [18] [19] [20] or a lipopolymer 16, 18 acting as a steric stabilizer improved transfection. Therefore we tested the implications of such modifications to the process of lipoplex-induced hemagglutination using lipoplexes based on liposomes of into DOTAP/CHOL-DNA lipoplexes resulted in slightly decreased agglutination of RBC after incubation of complexes in serum (Figures 5 and 6 ). This partial protection can be explained by the steric barrier the grafted PEG moiety contributes to the lipoplex, which reduces interaction of complexes with blood components and with cell surfaces. 16, 18 The formulation containing protamine sulfate showed the strongest interaction with RBC in all media. However, this effect was mostly due to the hemagglutination activity of protamine sulfate itself.
Effect of potential artifacts
Effect of anticoagulant: Two media (plasma, LMWC) contain sodium citrate anticoagulant, while the others do not (serum, HMWC, 0.15 M NaCl). As the anticoagulant may introduce an artifact, we added sodium citrate anticoagulant to the fractions that are anticoagulant-free to imitate the concentration in the plasma. A comparison between 0.15 M NaCl solutions with and without anticoagulant and HMWC with and without anticoagulant showed in both cases that citrate anticoagulant caused reduction in agglutination ( Figure 7) .
Effect of pH:
We demonstrated that the final pH of the reaction mixture influences the interaction of lipoplexes with RBC. When the reaction was carried out at pH 6.9 (when RBC are suspended in PBS:5% dextrose, 1:2 v/v), the level of agglutination obtained was higher in the HMWC and plasma media (Figure 8 ) than at physiological pH (7.4) . In addition, the order of protection against hemagglutination, comparing the various media, was also changed. At pH 6.9 it was 0.15 M NaCl > plasma > HMWC, while at pH 7.4 it was serum > HMWC > 0.15 M NaCl, probably because of the effect of medium pH on the net charge of the protein molecules, as the pH has no effect in protein-free medium (0.15 M NaCl) ( Figure  8 ).
Discussion
The basic finding of this study is that lipoplexes (and probably polyplexes), when positively charged and in contact with blood, induce hemagglutination. This agglutination is strongly affected by the milieux in which the lipoplexes and RBC occur and it may affect biodistribution of lipoplexes and/or transgene activity. In most cases lipoplexes used for transfection in vivo are positively charged. 16, 17, 20 Therefore it is expected that they will interact with negatively charged plasma proteins (such as albumin and gamma globulins), as well as with RBC, which are also negatively charged. 35 Our results (Table 1) show that most of the plasma proteins (approximately 80%) are present in the HMWC. Thẽ 20% lower value (when compared with plasma) results from precipitation, possibly due to the low ionic strength of HMWC (see conductivity results). Similarly, most Gene Therapy Figure 1) (~80%) of the plasma primary amino groups originate from the HMWC. The ratio of primary amino groups to total protein in the plasma and the HMWC is similar, suggesting that with respect to charge, the protein loss is not selective. It is clear that the effect of the LMWC on lipoplex-RBC interactions is mainly due to LMWC ionic strength and not due to compounds having primary amino groups. Indeed, the effects of LMWC and 0.15 M NaCl are very similar. A comparison between different media tested revealed that the protection against agglutination at physiological pH (7.4) follows the order: serum > HMWC > 0.15 M NaCl > 5% dextrose (ie serum gives the best protection against agglutination). A recent publication 9 demonstrated that injection of complexes of DOTAP/CHOL in a large volume of NaCl (800 l) enhances transfection in the mouse lung dramatically in comparison with the injection of those complexes in 500 Figure 8 Effect of pH (6.9 and 7.4) Figure 1 ) after addition of 1% RBC.
Figure 5 Effect of lipoplex composition and medium on agglutination. Degree of agglutination (according to the scale in Figure 1) of four different formulations containing DOTAP/CHOL in different charge ratios 0.5-6.0 (L
+ /DNA Ϫ ), after incubation in different media.
Figure 6 Minimal amount of cationic lipid (in nmol) causing significant agglutination (degree 2-3, according to the scale in
l and 200 l of NaCl. This large volume dilutes the mouse serum at least two-fold. These findings can be explained by our results, which demonstrate that serum inhibits hemagglutination better than NaCl.
We found that agglutination of RBC with no hemolysis is a common event caused by electrostatic interaction 36 A recent publication 37 indicates that the binding fraction (percent of dose) of cationic lipoplexes containing DOTMA/CHOL, DOTMA, or DOTMA/DOPE to blood cells increases with the increase in charge ratio (+/Ϫ). The degree of agglutination increases with increasing +/Ϫ charge ratio ( Figure 5 ). Loisel et al 9 also demonstrate a large enhancement of transfection efficiency in the lungs when the +/Ϫ charge ratio increased from 4.0 to 8.0 for various cationic lipids including DOTAP/CHOL. We suggest that this is related to agglutination. They also showed lack of transfection at +/Ϫ charge ratio of 1.0, conditions under which no hemagglutination occurs (Figures 2, 4 , and 5).
Neutral liposomes (DOPC/CHOL-DNA or DOPC/DOPE-DNA) caused no agglutination in 7:1 mole ratio, indicating that both helper lipids (CHOL and DOPE) are not involved in the agglutination. Increasing DNA to DOTAP mole ratio in lipoplexes (DOTAP/CHOL-DNA) reduced the extent of agglutination (Figure 2) . Figure 3 shows the interaction between F-PE lipoplexes and plasma. The decrease in the ratio F(lipp/p)/F(lipp/b) indicates the extent of interaction between plasma and lipoplexes; the lower the ratio, the higher the interaction. This ratio decreased with increased plasma concentration. Increasing the amount of DNA in the complex resulted in a smaller effect of plasma. The lower interaction is due to neutralization of Gene Therapy cationic lipid positive charge by negatively charged phosphate groups of DNA, which reduces the electrostatic attraction between negatively charged proteins of plasma and the lipoplexes. The fact that DNA reduces the interaction of plasma components with lipoplexes ( Figure 3) indicates that DNA has a greater affinity than plasma proteins to the cationic lipid. Therefore plasma proteins show no effect in 25% plasma, while at high plasma concentration (90%), there is a dramatic effect.
Sodium citrate decreases agglutination (Figure 7) . It is likely that the effect of LMWC in inhibition of agglutination derives from its ionic strength, which suppresses the surface charges of lipoplexes, RBC, and proteins, while the enhancement of protection derives from the anticoagulant, reducing lipoplex attraction to RBC and serum proteins. For this reason we used 0.15 M NaCl as a medium to give us information about the role of ionic strength of LMWC in protection against agglutination. All other media (ie serum, HMWC, 5% dextrose) were anticoagulant-free. Therefore using plasma (obtained in the presence of citrate anticoagulant) led to an underestimation of the hemagglutination. This effect of the anticoagulant is not surprising. It was already established that EDTA interacts with cationic liposomes. 38 These two anticoagulants share being poly-anionic (tri-and tetravalent for citrate and EDTA, respectively), thereby interacting with the cationic lipoplexes and reducing their charge.
Lipoplex-induced RBC agglutination with no hemolysis is a general phenomenon caused by an electrostatic interaction between positively charged assemblies, polyelectrolytes, and negatively charged RBC. Blood proteins, blood ionic strength, and pH affect this interaction. Artifacts in this process are introduced by anticoagulants, which reduce the net positive charge of the complex and therefore inhibit agglutination. The agglutinates formed by interaction between positively charged complexes and RBC may account for the biodistribution of transgene expression (lung >> liver Ն spleen) after i.v. administration of complexes. 16, 17, 20, 39, 40 The relevance of hemagglutination is also supported by a recent study of Sakurai et al. 41 Further studies are needed on the influence of agglutination on the toxicity and efficiency of transfection in vivo. ) was obtained from BioLab (Jerusalem, Israel) 2Ј-(1Љ,2Љ-dioleoyloxypropyldimethyl ammonium bromide)-N-ethyl-6-amidospermine tetratrifluoroacetic acid salt (DOSPA) was a gift from Dr Marilyn Ferrari (Vical, San Diego, CA, USA). Cholesterol, protamine sulfate, and spermidine were obtained from Sigma (St Louis, MO, USA). SuperFect was obtained from QIAGEN (Hilden, Germany). Based on TLC analysis, 10 ,42 the purity of all lipids used was Ն98.0%.
Materials and methods
DNA preparation
An Escherichia coli containing the plasmid pCMV-GH (a 4.8 kbp plasmid containing a gene coding for human growth hormone, hGH) 43 was a gift of Dr O Meuhas, Department of Biochemistry, Hebrew University. 43 DNA was purified using the plasmid Mega kit of QIAGEN.
The freshly prepared DNA was analyzed on agarose gel electrophoresis (1%) using post-staining with SYBR Green I fluorescent dye (Molecular Probes, Eugene, OR, USA). The quantitative analysis was performed with a computerized Fujifilm Fluorescent Image Analyzer FLA-2000 (Fuji Photofilm, Japan) 44 using an excitation wavelength of 473 nm, and an emission wavelength of 520 nm. The analysis showed the plasmid DNA was 85-90% in a supercoiled form and that there was no genomic DNA or RNA present. UV-spectroscopy showed no presence of protein or RNA contamination in the several DNA batches, as the ratio A 260 /A 280 was between 1.8 and 1.9, and the absorbance at 320 nm was negligible.
The concentration of DNA was quantified by determination of organic phosphate 7, 42 and is expressed as equivalent concentration of organic phosphate, which represents DNA negative charges. 1 Liposome preparation Multilamellar large vesicles (MLV) were prepared by freeze-drying overnight mixtures of DOTAP/CHOL, DOPC/CHOL, DOPC/DOPE, and DOTAP/DOPE (in mole ratio 1:1 or 1:2) dissolved in tert-butanol. The lyophilized cake was hydrated with 5% dextrose and vortexed for several minutes to form MLV. 45 MLV were downsized to form 50-nm small unilamellar vesicles (SUV), using the extrusion system LipoSofast 16, 18 DOSPA lipoplexes were prepared (Table 2) 
Preparation of electrical surface potential-sensitive fluorescent lipoplex to determine lipoplex-plasma interactions
Liposomes of DOTAP/CHOL/F-PE (1:1:0.002 mole ratio) were prepared as described above (liposome preparation). Liposomes (containing 15, 60, 75, 300 nmol cationic lipid) were diluted in various amounts of 20 mM Hepes buffer pH 7.4 (150, 1125, and 1425 l Hepes). One minute after dilution the fluorescence of liposomes in buffer was measured. DNA (30, 150 nmol) was added to form lipoplexes having charge ratios of 0.5 and 2.0 Ϫ/+. Four minutes after DNA addition the fluorescence of lipoplexes in Hepes, F(lipp/b), was measured. Either 1350, 375, or 75 l of plasma was added (to achieve a final plasma concentration of 90%, 25%, or 5%, respectively, in a total volume of 1.5 ml). Ten minutes after plasma addition, equilibrium was reached, and fluorescence of lipoplexes in plasma, F(lipp/p), was measured. The fluorescence intensity was determined at 37°C under stirring, using a Perkin-Elmer LS 50B Luminescence Spectrometer (Beaconsfield, UK) (excitation at 507 nm and emission at 528 nm). Each sample was measured in triplicate.
Serum and plasma fraction preparation
Serum preparation: A human blood sample without anticoagulant was allowed to stand for several hours until coagulation occurred and until complete separation of serum and RBC occurred. Serum was collected and centrifuged at 2000 r.p.m. at 4°C for 10 min to remove traces of RBC.
Plasma and plasma fraction preparation: Anticoagulant solution, citrate-phosphate-dextrose (63 ml), was added to 450 ml human blood. Anticoagulant solution (63 ml) contains 1.66 g sodium citrate, 206 mg citric acid, 140 mg monobasic sodium phosphate, and 1.61 g dextrose. Blood was centrifuged to separate the plasma from RBC. We dialyzed 150 ml of this plasma using a 14-kDa cut-off pore-size membrane against 900 ml highly purified water. The LMWC fraction (Յ14 kDa) was lyophilized and resuspended in 129 ml highly purified water. The pH of this fraction was adjusted to 7.4 after addition of Hepes to a final concentration of 20 mM. This fraction contains 6/7 of the total amount of the anticoagulant (36 ml). The HMWC (>14 kDa) underwent three more replacements of the dialysis medium, and therefore it is likely that this fraction does not contain anticoagulant. Then the pH was adjusted to 7.4 after addition of Hepes to a final concentration of 20 mM.
RBC preparation
For most studies, we used fresh human blood of B + type and sodium citrate as anticoagulant. The plasma and buffy coat were discarded. The RBC were washed five times with PBS (centrifuging at 2000 r.p.m. at 4°C). For a solution of final pH 6.9, the packed RBC collected after the last washing were resuspended in PBS:5% dextrose (1:2) to a final concentration of 1%. For a solution of final pH 7.4, Hepes was added to 5% dextrose to a concentration of 20 mM, and the pH was adjusted to 7.4 with HCl. This solution was used to make a 1% (v/v) suspension of RBC.
General procedure for agglutination determination
Five microliters of complex (Table 2 ) was incubated with 10 l medium (plasma, serum, HMWC, HMWC + anticoagulant, LMWC, 0.15 M NaCl, 0.15 M NaCl + anticoagulant, or 5% dextrose) for 30 min at RT. This suspension was diluted 1:100 by addition of 1.5 ml 5% dextrose. To 150 l of this solution, 100 l of 1% RBC suspension was added. Several hours after incubation, the samples were evaluated for the degree of agglutination according to the scale that is presented in Figure 1 .
Characterization of media
Total protein was determined by the method of Lowry et al. 48, 49 Determination of primary amino groups was done by the TNBS method. 47 Conductivity measurements were
Gene Therapy done in a V-TECH Oyster pH, temperature, conductivity meter (St Louis, MO, USA) at 37°C. Osmolality measurements were done in a WESCOR Vapor Pressure Osmometer 550 (Logan, UT, USA).
General
All other chemicals were analytical grade or better. All solutions were prepared with highly purified water from the WaterPro PS HPLC/Ultrafilter Hybrid (LABCONCO, Kansas City, MO, USA) system, which provides low levels of total carbon and of inorganic ions in sterile pyrogen-free water, of resistance 18.2 M⍀.
